Stronger rock solid buy10 May 2024 07:08
On top of the trialists. This is the sign of the surge upwards to never look back. Well done holders who didn't papp themselves.
Polarean Imaging plc
("Polarean" or the "Company")
New Xenon MRI System order received
Top-tier academic hospital becomes the first de novo site in the southeast U.S
Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces that it has received its second de novo order for a new Xenon MRI System from the University of Alabama at Birmingham ("UAB") Hospital, a top-tier academic hospital in the south-eastern region of the U.S. The 'de novo' designation indicates that UAB Hospital is acquiring this innovative imaging technology for the first time, without a prior research programme utilising the Polarean Xenon MRI System. This milestone underscores the increasing adoption and impact of Polarean's cutting-edge MRI solutions.
The Company expects to install the new system later this year and will collaborate closely with the hospital team, as it does with its existing clinical sites, to develop a strong Xenon MRI programme. This programme will support clinical imaging, NIH-funded research, and pharmaceutical-sponsored trials, aligning with Polarean's commitment to advancing medical research and patient care.
Christopher R. von Jako, Ph.D., CEO of Polarean, said: "Expanding our user base is one of the five key growth pillars we identified last year, and so I am delighted to have received our second de novo system order from UAB Hospital, a prestigious top-tier U.S. academic facility. Hospital acquisition of new capital equipment can be a lengthy process, and so momentum continues to build for our sales success. Contingent on the installation of this polariser system, and the two additional previously announced system orders, during 2024, the Company has completed sales and firm orders as of today that would result in 2024 revenue of approximately $2.5M. We expect additional orders to come in this year that will result in additional 2024 revenue. We are very excited to see that our commercial growth strategy is yielding tangible results."
Alex Dusek, Chief Commercial Officer of Polarean, said: "Feedback on the Polarean technology from physicians continues to be overwhelmingly positive, and we look forward to working closely with clinicians and scientists at UAB hospital to help establish the approved use of XENOVIEW™ for the visualisation of ventilation patients aged 12 and older. We are continuing to have productive meetings with our other high-priority centres, as they work through the necessary steps of the value assessment and procurement process. These centres are becoming increasingly aware of our technology's clinical, scientific, and economic value in lung ventilation, as well as research into gas exchange and cardiopulmonary for future applications, where we recently strengthe
Sign In
Follow the stocks
